China

Chime Bio, flush with $190M, blueprints major biomanufacturing boost in China
Chime Bio, flush with $190M, blueprints major biomanufacturing boost in China
Fierce Pharma
Chime Bio
CDMO
drug manufacturing
China
Flag link:
Pfizer halts biosimilar programs in crowded China market, sells plant to WuXi Biologics
Pfizer halts biosimilar programs in crowded China market, sells plant to WuXi Biologics
Fierce Pharma
Pfizer
China
biosimilars
WuXi Biologics
Flag link:
Bristol Myers offloading Swiss tablet and capsule plant to Chinese CDMO WuXi STA
Bristol Myers offloading Swiss tablet and capsule plant to Chinese CDMO WuXi STA
Fierce Pharma
Bristol-Myers Squibb
CDMO
China
WuXi Biologics
ISTA Pharmaceuticals
Flag link:
Illumina Partners with Sequoia Capital for its 3rd Life Science Incubator, This One in China
Illumina Partners with Sequoia Capital for its 3rd Life Science Incubator, This One in China
BioSpace
Illumina
Sequoia
incubators
China
Flag link:
Sinopharm claims COVID-19 vaccine safe in kids aged 3 and up
Sinopharm claims COVID-19 vaccine safe in kids aged 3 and up
Fierce Biotech
Sinopharm
China
COVID-19
vaccines
pediatric
Flag link:
Fast-expanding Shanghai Pharma breaks ground on $1.8B biotech park focused on next-gen R&D, antibody production
Fast-expanding Shanghai Pharma breaks ground on $1.8B biotech park focused on next-gen R&D, antibody production
Endpoints
China
Shanghai Pharmaceutical
R&D
Flag link:
Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?
Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?
Fierce Biotech
China
COVID-19
Gilead Sciences
remdesivir
Folotyn
Acrotech Biopharma
Flag link:
China’s Sinopharm Claims COVID-19 Vaccine has 79% Efficacy
China’s Sinopharm Claims COVID-19 Vaccine has 79% Efficacy
BioSpace
Sinopharm
China
COVID-19
vaccines
clinical trials
Flag link:
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Fierce Pharma
Merck
Bristol-Myers Squibb
AstraZeneca
Roche
Keytruda
Opdivo
Imfinzi
Tecentriq
China
PD-1 inhibitors
Flag link:
Allogene, broadening its reach, helps start a new biotech in China
Allogene, broadening its reach, helps start a new biotech in China
BioPharma Dive
Allogene
Overland Pharmaceuticals
China
cell therapies
Allogene Overland Pharma
Flag link:
BioNTech, Fosun start COVID-19 vaccine trial to support Chinese approval
BioNTech, Fosun start COVID-19 vaccine trial to support Chinese approval
Fierce Biotech
BioNTech
Fosun Pharmaceutical
China
clinical trials
vaccines
COVID-19
Flag link:
Pfizer hands LianBio $70M to tag along Perceptive's China play, with an eye to beefing up regional portfolio
Pfizer hands LianBio $70M to tag along Perceptive's China play, with an eye to beefing up regional portfolio
Endpoints
China
Pfizer
Perceptive Advisors
LianBio
Flag link:
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
Endpoints
JW Therapeutics
IPOs
CAR-T
liso-cel
China
Hong Kong
Juno Therapeutics
WuXi AppTec
Flag link:
Biden And Trump Drug Pricing Policies Would Decimate Biotech, Drive Innovation To China
Biden And Trump Drug Pricing Policies Would Decimate Biotech, Drive Innovation To China
Forbes
Joe Biden
Donald Trump
2020 Presidential election
drug pricing
innovation
pharma industry
China
Flag link:
FDA reissues Chinese respirator EUA, but freezes new additions
FDA reissues Chinese respirator EUA, but freezes new additions
RAPS.org
FDA
China
devices
Emergency Use Authorization
COVID-19
Flag link:
Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact
Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact
Endpoints
Pfizer
China
CStone
cancer
Flag link:
Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Endpoints
Junshi Biosciences
China
Merck
Innovent
nasopharyngeal carcinoma
toripalimab
Flag link:
China’s Junshi hits immuno-oncology milestone with breakthrough designation from FDA
China’s Junshi hits immuno-oncology milestone with breakthrough designation from FDA
MedCity News
China
Junshi Biosciences
immuno-oncology
toripalimab
nasopharyngeal carcinoma
FDA
Flag link:
Chinese drug firm says thousands have been vaccinated for COVID-19 on an emergency use scheme
Chinese drug firm says thousands have been vaccinated for COVID-19 on an emergency use scheme
Pharmafile
China
vaccines
COVID-19
Flag link:
Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi
Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi
Endpoints
Eli Lilly
Lilly Asia Ventures
AstraZeneca
China
R&D
Dizal Pharmaceutical
Flag link:

Pages